Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.

“We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting,” said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences. “The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation.”

“Our innovative energy delivery platform technology allows us to uniquely meet the needs of both cardiac surgeons and EPs who together treat all types of patients with cardiac ailments,” added President and Chief Executive Officer Burke T. Barrett. “I am looking forward to speaking with, now as part of Pulse Biosciences, the many providers in the clinical community I have met over the years.”

CellFX nsPFA technology will be featured at the following times at the HRS 2024 Annual Meeting:

Thursday, May 16, 2024
PFA Live Case Summit
Time:	1:30pm to 3:00pm ET
Location:	Boston Convention & Exhibition Center, Room 210BC
	Session III - Live/Recorded PFA Cases
	Live Case: PVI+ with Nanosecond PFA (CellFX nsPFA; Pulse Biosciences)
	Live Case Site: Na Homolce Hospital
	Live Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD, PhD
Friday, May 17, 2024
Presentation | Understanding Novel Ablation Technologies: Insights from Biophysics and Preclinical Studies
Time:	1:25pm to 1:30pm ET
Location: